Zobrazeno 1 - 10
of 121
pro vyhledávání: '"Carl M Gay"'
Autor:
Maliazurina B Saad, PhD, Lingzhi Hong, MD, Muhammad Aminu, MD, Natalie I Vokes, MD, Pingjun Chen, PhD, Morteza Salehjahromi, PhD, Kang Qin, MD, Sheeba J Sujit, PhD, Xuetao Lu, PhD, Elliana Young, MS, Qasem Al-Tashi, PhD, Rizwan Qureshi, PhD, Carol C Wu, ProfMD, Brett W Carter, ProfMD, Steven H Lin, ProfMD, Percy P Lee, ProfMD, Saumil Gandhi, MD, Joe Y Chang, ProfMD, Ruijiang Li, PhD, Michael F Gensheimer, MD, Heather A Wakelee, ProfMD, Joel W Neal, MD, Hyun-Sung Lee, MD, Chao Cheng, PhD, Vamsidhar Velcheti, ProfMD, Yanyan Lou, MD, Milena Petranovic, MD, Waree Rinsurongkawong, PhD, Xiuning Le, MD, Vadeerat Rinsurongkawong, PhD, Amy Spelman, PhD, Yasir Y Elamin, MD, Marcelo V Negrao, MD, Ferdinandos Skoulidis, MD, Carl M Gay, MD, Tina Cascone, MD, Mara B Antonoff, MD, Boris Sepesi, MD, Jeff Lewis, BS, Ignacio I Wistuba, ProfMD, John D Hazle, ProfPhD, Caroline Chung, MD, David Jaffray, ProfPhD, Don L Gibbons, ProfMD, Ara Vaporciyan, ProfMD, J Jack Lee, ProfPhD, John V Heymach, ProfMD, Jianjun Zhang, MD, Jia Wu, PhD
Publikováno v:
The Lancet: Digital Health, Vol 5, Iss 7, Pp e404-e420 (2023)
Summary: Background: Only around 20–30% of patients with non-small-cell lung cancer (NCSLC) have durable benefit from immune-checkpoint inhibitors. Although tissue-based biomarkers (eg, PD-L1) are limited by suboptimal performance, tissue availabil
Externí odkaz:
https://doaj.org/article/0a63dfd25a6f4694ab5c9c636dd7ce6b
Autor:
Jianhua Zhang, Hao Xu, Alexandre Reuben, Brian Alexander, Jack Lee, Tina Cascone, Jianjun Zhang, Kyle G Mitchell, Marcelo V Negrao, Stephen G Swisher, John V Heymach, Don L Gibbons, Jack A Roth, Ferdinandos Skoulidis, Yasir Y Elamin, Xiuning Le, Anne Tsao, Chang-Jiun Wu, Vincent A Miller, Bonnie S Glisson, Karthikeyan Murugesan, Meagan Montesion, Garrett Frampton, Katja Schulze, Ilze Bara, Vincent Shen, Sylvia Hu, Dawen Sui, Michael E Goldberg, David S Barreto, Jacqulyne P Robichaux, Carl M Gay, Lingzhi Hong, Waree Rinsurongkawong, Vassiliki Papadimitrakopoulou, Gaurav Singal, Lee A Albacker, David Shames
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Background Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels. W
Externí odkaz:
https://doaj.org/article/deb634044c5641f5a4d7746a8b39b598
Autor:
Jorge Carretero-Ortega, Zinal Chhangawala, Shane Hunt, Carlos Narvaez, Javier Menéndez-González, Carl M Gay, Tomasz Zygmunt, Xiaochun Li, Jesús Torres-Vázquez
Publikováno v:
eLife, Vol 8 (2019)
Semaphorins (SEMAs) and their Plexin (PLXN) receptors are central regulators of metazoan cellular communication. SEMA-PLXND1 signaling plays important roles in cardiovascular, nervous, and immune system development, and cancer biology. However, littl
Externí odkaz:
https://doaj.org/article/8b95a9a637674fcb8d8850945bec54b5
Autor:
Ying Jin, Yuefeng Wu, Alexandre Reuben, Liang Zhu, Carl M. Gay, Qingzhe Wu, Xintong Zhou, Haomin Mo, Qi Zheng, Junyu Ren, Zhaoyuan Fang, Teng Peng, Nan Wang, Liang Ma, Lungevity PANSHI Initiative Consortium, Yun Fan, Hai Song, Jianjun Zhang, Ming Chen
Publikováno v:
Cell Discovery, Vol 10, Iss 1, Pp 1-19 (2024)
Abstract Small cell lung cancer (SCLC) is an aggressive pulmonary neuroendocrine malignancy featured by cold tumor immune microenvironment (TIME), limited benefit from immunotherapy, and poor survival. The spatial heterogeneity of TIME significantly
Externí odkaz:
https://doaj.org/article/13c7204465ef49f6b7c5296892d33b0a
Autor:
Mingchao Xie, Miljenka Vuko, Jaime Rodriguez-Canales, Johannes Zimmermann, Markus Schick, Cathy O’Brien, Luis Paz-Ares, Jonathan W. Goldman, Marina Chiara Garassino, Carl M. Gay, John V. Heymach, Haiyi Jiang, J. Carl Barrett, Ross A. Stewart, Zhongwu Lai, Lauren A. Byers, Charles M. Rudin, Yashaswi Shrestha
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-17 (2024)
Abstract Background We explored potential predictive biomarkers of immunotherapy response in patients with extensive-stage small-cell lung cancer (ES-SCLC) treated with durvalumab (D) + tremelimumab (T) + etoposide-platinum (EP), D + EP, or EP in the
Externí odkaz:
https://doaj.org/article/dac90161c2bf43f78841723ad0ac6b3b
Autor:
Sehhoon Park, Tae Hee Hong, Soohyun Hwang, Simon Heeke, Carl M. Gay, Jiyeon Kim, Hyun-Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Jong Ho Cho, Yong Soo Choi, Jhingook Kim, Young Mog Shim, Hong Kwan Kim, Lauren Averett Byers, John V. Heymach, Yoon-La Choi, Se-Hoon Lee, Keunchil Park
Publikováno v:
EBioMedicine, Vol 102, Iss , Pp 105062- (2024)
Summary: Background: Recent studies have reported the predictive and prognostic value of novel transcriptional factor-based molecular subtypes in small-cell lung cancer (SCLC). We conducted an in-depth analysis pairing multi-omics data with immunohis
Externí odkaz:
https://doaj.org/article/40a1e82c84034502bbbe4835972d5109
Autor:
Bingnan Zhang, MD, MBA, Whitney Lewis, PharmD, C. Allison Stewart, PhD, Benjamin B. Morris, PhD, Luisa M. Solis, MD, Alejandra Serrano, MD, Yuanxin Xi, PhD, Qi Wang, PhD, Elyse R. Lopez, MD, Kyle Concannon, MD, Simon Heeke, PhD, Ximing Tang, MD, PhD, Gabriela Raso, MD, Robert J. Cardnell, PhD, Natalie Vokes, MD, George Blumenschein, MD, Yasir Elamin, MD, Frank Fosella, MD, Anne Tsao, MD, Ferdinandos Skoulidis, MD, PhD, Celyne Bueno Hume, MD, Koji Sasak, MD, PhD, Jeff Lewis, BS, Waree Rinsurongkawong, PhD, Vadeerat Rinsurongkawong, PhD, Jack Lee, PhD, Hai Tran, PhD, Jianjun Zhang, MD, PhD, Don Gibbons, MD, PhD, Ara Vaporciyan, MD, Jing Wang, PhD, Keunchil Park, MD, PhD, John V. Heymach, MD, PhD, Lauren A. Byers, MD, Carl M. Gay, MD, PhD, Xiuning Le, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100623- (2024)
Introduction: NSCLC transformation to SCLC has been best characterized with EGFR-mutant NSCLC, with emerging case reports seen in ALK, RET, and KRAS-altered NSCLC. Previous reports revealed transformed SCLC from EGFR-mutant NSCLC portends very poor p
Externí odkaz:
https://doaj.org/article/ff328939b00e48428ec63183f24ee037
Autor:
Carminia Maria Della Corte, Morena Fasano, Vincenza Ciaramella, Flora Cimmino, Robert Cardnell, Carl M. Gay, Kavya Ramkumar, Lixia Diao, Raimondo Di Liello, Giuseppe Viscardi, Vincenzo Famiglietti, Davide Ciardiello, Giulia Martini, Stefania Napolitano, Concetta Tuccillo, Teresa Troiani, Erika Martinelli, Jing Wang, Lauren Byers, Floriana Morgillo, Fortunato Ciardiello
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-10 (2022)
Abstract Background We recently conducted Cetuximab-AVElumab-Lung (CAVE-Lung), a proof-of-concept, translational and clinical trial, to evaluate the combination of two IgG1 monoclonal antibodies (mAb): avelumab, an anti-PD-L1 drug, and cetuximab, an
Externí odkaz:
https://doaj.org/article/bf73de6b841a47699632ecd99243d1f4
Autor:
Ming Chen, Runzhe Chen, Ying Jin, Jun Li, Xin Hu, Jiexin Zhang, Junya Fujimoto, Shawna M. Hubert, Carl M. Gay, Bo Zhu, Yanhua Tian, Nicholas McGranahan, Won-Chul Lee, Julie George, Xiao Hu, Yamei Chen, Meijuan Wu, Carmen Behrens, Chi-Wan Chow, Hoa H. N. Pham, Junya Fukuoka, Jia Wu, Edwin Roger Parra, Latasha D. Little, Curtis Gumbs, Xingzhi Song, Chang-Jiun Wu, Lixia Diao, Qi Wang, Robert Cardnell, Jianhua Zhang, Jing Wang, Xiuning Le, Don L. Gibbons, John V. Heymach, J. Jack Lee, William N. William, Chao Cheng, Bonnie Glisson, Ignacio Wistuba, P. Andrew Futreal, Roman K. Thomas, Alexandre Reuben, Lauren A. Byers, Jianjun Zhang
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Small-cell lung cancer (SCLC) is an aggressive disease with limited therapeutic options. Here the authors perform an immunogenomic analysis of limited-stage SCLC, revealing a homogeneous mutational landscape, but limited T-cell infiltration and a col
Externí odkaz:
https://doaj.org/article/61c0fcf9baf94acab6feccd225cfafb0
Publikováno v:
Molecular Cell. 83:660-680